Pneumonia, Bacterial
Recent clinical, regulatory, research and industry developments relating to this disease.
The Rise of Non-Tuberculosis Mycobacterial Lung Disease.
Diagnosis of severe respiratory infections in immunocompromised patients.
BTS guidelines for the management of community acquired pneumonia in adults: update 2009.
Deaths from bacterial pneumonia during 1918-19 influenza pandemic.
What's happening now
An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.
- 1 clinical trial expected to report results, the earliest in Q4 2026.
Clinical MilestonesViewHide
- 2026-02-10A Randomized, Double-Blind, Placebo-Controlled Multicenter Study to Evaluate the Efficacy and Safety of CAL02 Administered Intravenously in Addition to Standard of Care in Subjects With Severe Community-Acquired Bacterial Pneumonia (SCABP)Primary completion
- 2025-09-18A Phase 2, Randomized, Double-blind, Multi-dose, Dose Finding Study to Evaluate the Safety, Tolerability and Immunogenicity of AFX3772 Compared With PCVs in Healthy InfantsCompleted
- 2026-05-27ClinicalA Phase 1, Observer-Blind, Randomized, Active Controlled Trial to Evaluate the Safety and Immunogenicity of an Investigational Pneumococcal Vaccine in Adults 50 To 64 Years of AgeResults expected Q4 2026
- 2026-02-10ClinicalA Randomized, Double-Blind, Placebo-Controlled Multicenter Study to Evaluate the Efficacy and Safety of CAL02 Administered Intravenously in Addition to Standard of Care in Subjects With Severe Community-Acquired Bacterial Pneumonia (SCABP)Primary completion
- 2025-09-18ClinicalA Phase 2, Randomized, Double-blind, Multi-dose, Dose Finding Study to Evaluate the Safety, Tolerability and Immunogenicity of AFX3772 Compared With PCVs in Healthy InfantsCompleted
Therapeutic landscape
Therapies with a regulatory footing for this condition, alongside the wider set of agents co-studied with it in the literature.
Approval — Quofenix is indicated for the treatment of the following infections in adults: acute bac… (2019)
Clinical trials
The current development programme across all trial phases.
Regulatory timeline
Drug regulatory events matched to this condition by indication — EMA.
European Medicines Agency (CC BY 4.0). Events are matched to this condition by drug indication text — approvals/updates for drugs indicated for it, not disease-specific acts.
Research activity
Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.
Major themes7
- Pneumonia, Bacterial2
- Bacteriophages1
- Community-Acquired Infections1
- Disease Outbreaks1
- Immunity, Innate1
- Respiratory Tract Infections1
- Transcriptome1
Leading journals6
- Clinical infectious diseases : an official publication of the Infectious Diseases Society of America3
- Frontiers in immunology2
- American journal of respiratory and critical care medicine1
- Emerging infectious diseases1
- Frontiers in public health1
- Intensive care medicine1
Leading researchers8
- Anzueto A2
- Bartlett JG2
- Dean NC2
- File TM Jr2
- Metersky ML2
- Musher DM2
- Restrepo MI2
- Waterer GW2
Affiliations (unnormalised)6
- Anzhen hospital afflicted to Capital medical university1
- Armed Forces Health Surveillance Center1
- Brigham and Women's Hospital and Harvard Medical School Harvard Pilgrim Health Care Institute1
- Centre for Molecular Therapeutics1
- Centre for Tropical Bioinformatics and Molecular Biology1
- Centre National de Référence de Toxémies Staphylococciques1
Related conditions
Diseases frequently studied alongside this one. Number shows shared papers.
Disease profile
A grounded synthesis of the condition — overview, causes, mechanism, risk factors and current standard of care.
Bacterial pneumonia is inflammation of the lung parenchyma caused by bacterial infection. The literature covers it as a pulmonary infectious disease across community-acquired, hospital-acquired, and ventilator-associated settings, with attention to microbiology, pathology, immunology, epidemiology, genetics, and drug therapy.
The direct cause is bacterial infection of the lungs. The grounding also includes non-tuberculous mycobacterial lung disease as a bacterial pulmonary infection, and notes that bacterial pneumonia can occur in community, hospital, and ventilator-associated contexts.
The disease reflects host-pathogen interactions in the lung, where bacterial infection triggers inflammation in the lung parenchyma. The lung’s innate and adaptive immune responses shape the inflammatory outcome, and the literature highlights immunological differences between Gram-positive and Gram-negative bacterial pneumonia as well as pneumonia-associated acute lung injury.
Risk is increased by exposure to bacterial pathogens in community, hospital, or ventilator-associated settings. The grounding also indicates higher susceptibility in immunocompromised patients and in people with defective lung structure for some bacterial lung infections such as non-tuberculous mycobacterial disease.
Standard management is antibiotic therapy, including initial empiric antibiotic treatment guided by clinical setting and severity. The guidelines also address diagnostic testing and decisions about site of care for community-acquired pneumonia, and management of hospital-acquired and ventilator-associated pneumonia in hospitalized patients.
AI-generated summary grounded in MeSH and 6 peer-reviewed sources. Informational only — not medical advice. Generated 2026-07-07.
Reference
Authoritative identity, definition & identifiers.
Inflammation of the lung parenchyma that is caused by bacterial infections.
- Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
- Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
- Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
- Related entities are derived from literature co-mention (studied together) — associative, not causal.